SearchBar Icon

Hemochromatosis Therapeutics Pipeline Involves Development of Gene Suppressor Therapy

Published Date:   March 2018

Hyperlipidemia therapeutics currently exhibits a pipeline with nine drug candidates, accordiing to P&S Intelligence

Hemochromatosis Therapeutics Pipeline in 2018

Hemochromatosis or iron overload refer to the accumulation of excessive iron in the body. Iron chelation therapy is needed to remove this excess iron from the body. Hemochromatosis may be caused due to genetic disorders or acquired by multiple blood transfusions or consuming high levels of supplemental iron. High levels of iron in the body may damage the vital organs in the body.

Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of hemochromatosis are being developed to be administered by the subcutaneous route, which facilitates the absorption of the drug as iron chelator drugs such as deferoxamine, that are poorly absorbed from the gastrointestinal tract.

Access Report Summary with Detailed TOC on "Hemochromatosis/Iron Overload Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:

Hemochromatosis Therapeutics Pipeline is Driven by the Availability of the Limited Drug Options

As of now, there are three marketed iron chelator drugs available for the treatment of hemochromatosis namely; Deferasirox, Deferoxamine and Deferiprone. Limited competition gives companies investing in the hemochromatosis therapeutics pipeline an opportunity to gain market share. Thus, driving the growth of the hemochromatosis therapeutics pipeline.

Hemochromatosis Therapeutics Pipeline Involves Development of Gene Suppressor Therapy

Hemochromatosis most of the times develops as a hereditary disease. Therefore, it has been observed that the companies are developing drug candidates that suppresses the expression of genes. For instance, ALN-TMP by Alnylam Pharmaceuticals Inc. is under the Pre-Clinical phase of development for the treatment of hemochromatosis. The drug candidate is a Tmprss6 gene suppressor being developed using RNA interference (RNAi) technology.

Some of the key players involved in the development of hemochromatosis therapeutics include La Jolla Pharmaceutical Company, Silence Therapeutics plc, and Shire Plc.

Hemochromatosis Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company